Latest Period
Q4 2025
- Info
- Insider Trading
- Financials
- Holders
Security Snapshot
Kezar Life Sciences, Inc. - Common Stock (KZR) Institutional Ownership
CUSIP: 49372L209
13F Institutional Holders and Ownership History from Q2 2024 to Q4 2025
Institutions Reporting
43
Shares (Excl. Options)
4,460,455
Price
$6.29
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock
- Symbol
- KZR on Nasdaq
- Shares outstanding
- 7,437,095
- Price per share
- $6.83
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 4,460,455
- Total reported value
- $28,054,562
- % of total 13F portfolios
- 0%
- Share change
- +312,319
- Value change
- +$2,629,556
- Number of holders
- 43
- Price from insider filings
- $6.83
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- KZR - Kezar Life Sciences, Inc. - Common Stock is tracked under CUSIP 49372L209.
- 43 institutions reported positions in Q4 2025.
- 1 significant owner is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 38 to 43 between Q3 2025 and Q4 2025.
- Reported value moved from $16,401,762 to $28,054,562.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 43 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 49372L209?
CUSIP 49372L209 identifies KZR - Kezar Life Sciences, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Continue With The Right Next Step
- Latest 13F filings - identify new institutional portfolio moves.
- Latest Schedule 13D/13G reports - cross-check beneficial ownership events.
- All institutional ownership pages - compare nearby CUSIPs and holder concentration.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 49372L209:
Significant Owners of Kezar Life Sciences, Inc. - Common Stock (KZR) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Stonepine Capital Management, LLC | 2.1% | -62% | $968,310 | -$1,370,578 | 156,179 | -59% | Stonepine Capital Management, LLC | 31 Dec 2025 |
As of 31 Dec 2025, 43 institutional investors reported holding 4,460,455 shares of Kezar Life Sciences, Inc. - Common Stock (KZR). This represents 60% of the company’s total 7,437,095 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Kezar Life Sciences, Inc. - Common Stock (KZR) together control 59% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BML Capital Management, LLC | 9.7% | 720,787 | 0% | 4% | $4,533,750 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 9.6% | 716,759 | 0% | 0.11% | $4,508,414 |
| TANG CAPITAL MANAGEMENT LLC | 8.9% | 664,314 | -7.7% | 0.21% | $4,178,535 |
| VANGUARD GROUP INC | 4.6% | 341,404 | +27% | 0% | $2,147,431 |
| Nantahala Capital Management, LLC | 3.7% | 276,754 | 0.1% | $1,740,783 | |
| Affinity Asset Advisors, LLC | 3.1% | 229,076 | 0.1% | $1,440,888 | |
| Stonepine Capital Management, LLC | 2.1% | 156,179 | -59% | 0.78% | $982,366 |
| RENAISSANCE TECHNOLOGIES LLC | 1.8% | 131,285 | +13% | 0% | $825,783 |
| Peapod Lane Capital LLC | 1.7% | 126,699 | +0.74% | 0.68% | $796,937 |
| ACADIAN ASSET MANAGEMENT LLC | 1.7% | 125,371 | -6.1% | 0% | $787,000 |
| ADAR1 Capital Management, LLC | 1.6% | 117,440 | -6% | 0.06% | $738,698 |
| Ikarian Capital, LLC | 1.4% | 102,211 | -4.4% | 0.08% | $642,907 |
| BlackRock, Inc. | 1.3% | 98,684 | +0.59% | 0% | $620,722 |
| Rangeley Capital, LLC | 1.2% | 85,926 | 0.47% | $540,475 | |
| Aldebaran Capital, LLC | 1.1% | 80,630 | 0.45% | $507,163 | |
| GEODE CAPITAL MANAGEMENT, LLC | 0.92% | 68,167 | +4.1% | 0% | $428,860 |
| PRELUDE CAPITAL MANAGEMENT, LLC | 0.71% | 52,929 | 0.02% | $332,923 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.69% | 51,638 | +26% | 0.01% | $324,803 |
| FNY Investment Advisers, LLC | 0.67% | 50,000 | 0.09% | $314,000 | |
| Vazirani Asset Management LLC | 0.65% | 48,428 | 1.8% | $304,612 | |
| Shay Capital LLC | 0.45% | 33,699 | -50% | 0.03% | $211,967 |
| RBF Capital, LLC | 0.38% | 28,144 | -0.39% | 0.01% | $177,026 |
| STATE STREET CORP | 0.36% | 27,093 | +28% | 0% | $170,415 |
| DIMENSIONAL FUND ADVISORS LP | 0.36% | 26,543 | +14% | 0% | $166,955 |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | 0.34% | 25,000 | 0% | 0.13% | $157,250 |
Institutional Holders of Kezar Life Sciences, Inc. - Common Stock (KZR) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 4,460,455 | $28,054,562 | +$2,629,556 | $6.29 | 43 |
| 2025 Q3 | 4,206,014 | $16,401,762 | -$1,447,302 | $3.90 | 38 |
| 2025 Q2 | 4,474,800 | $20,493,118 | +$639,707 | $4.58 | 38 |
| 2025 Q1 | 4,328,239 | $21,120,201 | +$284,256 | $4.88 | 40 |
| 2024 Q4 | 4,201,005 | $28,227,155 | +$18,320,837 | $6.72 | 42 |
| 2024 Q3 | 1,440,173 | $1,113,903 | +$1,099,753 | $0.77 | 3 |
| 2024 Q2 | 18,300 | $10,980 | +$10,980 | $0.60 | 1 |